EMA data disclosure policy needs a rethink, says industry
This article was originally published in Scrip
Comments submitted by the European industry federation EFPIA give some indication of the challenges facing the European Medicines Agency if it is to finalise and implement its new policy on the publication of clinical trial data by the 1 January 2014 deadline.
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.